Leading on from the receipt of our Investigational Medicinal Products (IMP-MA) manufacturing licence from the UK Government regulator, the MHRA, in early 2012, Symbiosis hosted its first full MHRA cGMP inspection in December 2012.Not surprisingly, we are delighted to share with you that the inspection was successfully concluded to the satisfaction of the MHRA.
This is another significant achievement for Symbiosis and is a positive reflection on the commitment of our team here at Symbiosis to delivering operational compliance of the highest standard. As we like to say: “Right first time, every time”.
Given our focus on continuous improvement, the feedback we receive from both regulator and client audits alike are integrated into the on-going revision of our quality strategy for 2013. We work to ensure that we not only meet, but actively strive to exceed our regulatory requirements wherever we can. This means we continue to actively develop our World Class quality system. That is in the best of our clients, and therefore an absolute priority for us.
Symbiosis Pharmaceutical Services specialise in the cGMP manufacture of liquid, lyophilized, cytotoxic, conventional and biological pharmaceuticals phase I and phase II clinical trials.
